Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SRTS · NASDAQ · Surgical & Medical Instruments & Apparatus
Sensus Healthcare (SRTS) · oqro.io/stocks/SRTS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.33−0.895 (−27.80%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Sensus Healthcare (SRTS) filed 8 open-market purchases in the last 90 days; the latest was filed on Aug 31, 2026.
Since 2016, Sensus Healthcare insiders reported 44 open-market purchases and 171 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
No open-market sale by an insider of Sensus Healthcare (SRTS) was filed with the SEC in the last 90 days.
No trade in Sensus Healthcare (SRTS) was disclosed by a member of Congress in the last 12 months.
Sensus Healthcare's next results are expected on Feb 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−47.9% (−$2.14) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $4.46 on Nov 13, 2025 to $2.33 on Nov 13, 2026 (−47.9%). Disclosed in this range: 14 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Boca Raton, Fl.
Last 12 months
−47.9%
Market value
$38.3M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 222K shares sold short (1.4% of shares outstanding), −3.3% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$6M
−12.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$11.5M
This quarter −$2.27M, a year earlier $2.29M
Net debt
—
Debt —, cash $12.9M, at Sep 30, 2026
Net income, last 12 months
−$16M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Revenue, fiscal 2025
$27.5M
−34.3% vs the year before
Net income, fiscal 2025
−$7.72M
A loss for the year
Shares outstanding
16.5M
As of Nov 10, 2026
In fiscal 2025 the company spent $300K buying back its own shares. Cash actually paid, from its cash-flow statement.
Traded Aug 28 – Aug 31, 2026 · largest single transaction ~$129K
Aug 28, 2026~$129K · 38K sh @ $3.44
Aug 31, 2026~$97K · 27K sh @ $3.54
DetailsOfficial recordTraded Aug 24 – Aug 27, 2026 · largest single transaction ~$113K
Aug 27, 2026~$35K · 11K sh @ $3.18
DetailsOfficial recordAug 26, 2026~$32K · 9,708 sh @ $3.29
DetailsOfficial recordAug 24, 2026~$113K · 35K sh @ $3.25
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
Nov 12, 2026
Within the 30 days after it, until Dec 12, 2026
Next results, expected
Feb 10, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
72%
31 of 43 insider purchases since 2016 came within 30 days after a results announcement
From Sensus Healthcare's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Sensus Healthcare's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Insiders of Sensus Healthcare reported 44 open-market purchases and 171 sales since 2016; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $576K10×10 trades | — |
| 2025 | $168K12×12 trades | — |
| 2024 | — | $123K2×2 trades |
| 2023 | $240K10×10 trades | — |
| 2022 | — | $5.16M16×16 trades |
| 2021 | — | $1.28M13×13 trades |
| 2020 | $263K11×11 trades | — |
| 2019 | — | $58K5×5 trades |
| 2018 | — | $1.05M65×65 trades |
| 2017 | — | $912K54×54 trades |
| 2016 | $53K1×1 trade | $23K16×16 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Changed auditor
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Against the S&P 500 over the year
Since Nov 12, 2025, SRTS is down 49.5% and the index fund is up 10.4%: 60 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SRTS moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.